Get the Stockscreener App
0.85
2.62%
-0.0229
After Hours:
.86
0.01
+1.18%
Oncolytics Biotech Inc stock is traded at $0.85, with a volume of 846.25K.
It is down -2.62% in the last 24 hours and down -22.73% over the past month.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.
See More
Previous Close:
$0.8729
Open:
$0.87
24h Volume:
846.25K
Relative Volume:
0.73
Market Cap:
$98.71M
Revenue:
-
Net Income/Loss:
$-21.32M
P/E Ratio:
-3.7862
EPS:
-0.2245
Net Cash Flow:
$-19.96M
1W Performance:
-4.48%
1M Performance:
-22.73%
6M Performance:
-18.27%
1Y Performance:
+69.90%
1-Day Range:
$0.8418
$0.8701
1-Week Range:
$0.8418
$0.92
52-Week Range:
$0.3258
$1.51
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Name
Oncolytics Biotech Inc
Sector
Industry
Phone
(403) 670-7377
Address
SUITE 325, 4350 EXECUTIVE DRIVE, SAN DIEGO, AB
Compare ONCY vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.85 | 101.37M | 0 | -21.32M | -19.96M | -0.2245 |
VRTX
Vertex Pharmaceuticals Inc
|
436.95 | 114.32B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
698.25 | 74.74B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
799.32 | 51.13B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.98 | 39.18B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
145.66 | 31.78B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-25 | Initiated | Lake Street | Buy |
| Oct-06-22 | Initiated | Maxim Group | Buy |
| Feb-17-21 | Initiated | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Stock (ONCY) Latest News
Oncolytics Biotech Inc.Common Stock (NQ: ONCY - FinancialContent
Oncolytics Biotech stock (CA6823101073): Q1 loss deepens and going concern warning puts focus on cas - AD HOC NEWS
Oncolytics Biotech (ONCY) doubles Q1 loss and warns on going concern - Stock Titan
"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies - GlobeNewswire Inc.
Oncolytics Biotech stock (CA6823101073): Q4 earnings miss and upcoming report - AD HOC NEWS
TradingKey - TradingKey
Oncolytics Biotech (ONCY) Eps Diluted (TTM) - Zacks Investment Research
Lobbying Update: $35,000 of ONCOLYTICS BIOTECH INC. lobbying was just disclosed - Quiver Quantitative
ONCY: Oncolytics BiotechInteractive Chart - Zacks Investment Research
Penny Stock Oncolytics Biotech Says Colorecatal Cancer Drug's Durability Tops Historical Benchmarks - MSN
Oncolytics Biotech’s Pelareorep Data Reshapes Colorectal Cancer And Investor Outlook - Sahm
Oncolytics Biotech Reports Data in Colorectal Cancer Study - IPO Edge
Oncolytics Biotech (ONCY) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum - Quantisnow
Oncolytics Biotech Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer, Pursues Accelerated FDA Approval for Pelareorep Therapy 7 - Minichart
Oncolytics Says Colorectal Cancer Drug Outperforms BenchmarksOncolytics Biotech (NASDAQ:ONCY) - Benzinga
Stocks In Play - Baystreet.ca
Oncolytics Biotech Inc - Baystreet.ca
Stocks in play: Oncolytics Biotech Inc - Barchart
Oncolytics Biotech Highlights Strong Pelareorep Data in Colorectal Cancer - TipRanks
Oncolytics Reports 19.5-Month Median Duration of Response in 2L KRAS-Mutant MSS mCRC - TradingView
Oncolytics Biotech® Reports Durable Responses In Second-Line Ras-Mutant Mss Colorectal Cancer - TradingView
A colorectal cancer study hit 19.5-month response duration as FDA talks start - Stock Titan
Durable mCRC responses spur FDA talks for Oncolytics Biotech (NASDAQ: ONCY) - Stock Titan
Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer - Yahoo Finance
CEO Chat with Jared Kelly, CEO of Oncolytics Biotech - Zacks Small Cap Research
$207B Market Shift: The Race for Fast Track Approval in Oncology - Quantisnow
Oncolytics Biotech Inc. (NASDAQ:ONCY) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
ONCY Stock Price, Quote & Chart | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill
Analysts Have Conflicting Sentiments on These Healthcare Companies: Oncolytics Biotech (ONCY) and Agilon Health (AGL) - The Globe and Mail
Lake Street Maintains Oncolytics Biotech(ONCY.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Oncolytics aligns with FDA on pivotal trial design for anal cancer By Investing.com - Investing.com South Africa
Oncolytics aligns with FDA on pivotal trial design for anal cancer - Investing.com UK
Oncolytics Biotech Aligns With FDA on Study Design for Pelareorep in Anal Cancer - marketscreener.com
Oncolytics (ONCY) Secures FDA Agreement on Pivotal Study Design - GuruFocus
Oncolytics Biotech Inc announces alignment with FDA on pivotal anal cancer study - marketscreener.com
Oncolytics Biotech Aligns with FDA on Pelareorep Trial - TipRanks
Oncolytics Biotech Aligns with FDA on Pivotal Study for Anal Cancer Immunotherapy Approval - Minichart
Oncolytics surges on FDA alignment for pivotal cancer trial By Investing.com - Investing.com India
Oncolytics Biotech | 8-K: Current report - Moomoo
Oncolytics surges on FDA alignment for pivotal cancer trial - Investing.com
Oncolytics aligns with FDA on randomized pivotal anal cancer trial for pelareorep - TradingView
Oncolytics Biotech (Nasdaq: ONCY) secures FDA alignment on pivotal anal cancer study design - Stock Titan
Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study - ChartMill
Oncolytics Could Re-Rate As Pelareorep Focuses On Registrational Paths (NASDAQ:ONCY) - Seeking Alpha
ONCY (Oncolytics Biotech Inc. Common Shares) posts wider Q3 2025 loss than consensus estimates, shares rise 5.66 percent.Social Investment Platform - Xã Thanh Hà
ONCY Should I Buy - Intellectia AI
Q1 EPS Forecast for Oncolytics Biotech Lifted by Analyst - MarketBeat
Published on: 2026-04-14 02:49:57 - baoquankhu1.vn
Equities Analysts Issue Forecasts for ONCY Q1 Earnings - MarketBeat
Oncolytics Biotech Inc Stock (ONCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Oncolytics Biotech Inc Stock (ONCY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kelly Jared | Chief Executive Officer |
Mar 12 '26 |
Buy |
0.96 |
5,050 |
4,848 |
114,050 |
| Kelly Jared | Chief Executive Officer |
Feb 12 '26 |
Buy |
0.84 |
29,500 |
24,839 |
109,000 |
| Kelly Jared | Chief Executive Officer |
Feb 11 '26 |
Buy |
0.84 |
5,600 |
4,682 |
79,500 |
| Look Kirk | Chief Financial Officer |
Feb 12 '26 |
Buy |
0.84 |
12,000 |
10,104 |
287,515 |
| Pisano Wayne | Director |
Feb 12 '26 |
Buy |
0.84 |
30,000 |
25,338 |
492,414 |
| Heineman Thomas Charles | Chief Medical Officer |
Feb 12 '26 |
Buy |
0.83 |
12,132 |
10,033 |
282,818 |
| Brown Deborah Margaret | Director |
Feb 12 '26 |
Buy |
0.85 |
25,000 |
21,240 |
109,851 |
| Hagerman Allison | VP, Product Development |
Feb 12 '26 |
Buy |
0.83 |
10,000 |
8,298 |
115,059 |
| Seizinger Bernd R. | Director |
Feb 11 '26 |
Buy |
0.83 |
60,000 |
49,590 |
526,991 |
| Seizinger Bernd R. | Director |
Feb 12 '26 |
Buy |
0.85 |
40,000 |
33,864 |
566,991 |
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):